N/A
N=82
Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Bottom Line
View on ClinicalTrials.gov: NCT01445730 ↗Enrolled (actual)
82
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Fructose (Dietary_supplement)
- Age
- Adult · 20+ yrs
- Sex
- Male
- Sponsor
- Marja-Riitta Taskinen
- Primary completion
- May 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY TG Plasma AUC |
1130; 1220 | 0.005 sig |
| PRIMARY B48 Plasma AUC |
7660; 8200 | 0.04 sig |
| PRIMARY TG Plasma iAUC |
377; 422 | 0.04 sig |
| SECONDARY DNL |
12.3; 16.5 | 0.005 sig |
| SECONDARY ApoC-III |
10.4; 11.2 | 0.006 sig |
| SECONDARY β-OH Butyrate |
0.699; 0.542 | 0.01 sig |
| SECONDARY Liver Fat |
6.66; 7.33 | 0.008 sig |
Summary
High fructose intake is increasingly recognized as causative in development of prediabetes, metabolic syndrome and cardiovascular disease (CVD). The mechanisms underlying fructose-induced metabolic disturbances are unclear but are beginning to be unraveled. In contrast to metabolism of glucose, the breakdown of fructose leads to the generation of metabolites that stimulate hepatic de novo lipogenesis (DNL) and increased levels of both fasting and postprandial triglycerides. The key lipogenic transcription factor seems to be activated by fructose independently of insulin. However, it is still controversial whether fructose consumption increases DNL in man to the extent that it induces metabolic disturbances. Animal studies have shown that also the adipose tissue is responsive to fructose feeding fructose, and that high fructose-feeding induces insulin resistance and inflammation in the adipose tissue. The role of intestinal insulin resistance in fructose-induced dysmetabolism has not been studied in detail. The critical question is whether the metabolic disturbances are induced by calorie excess or by fructose per se.
Eligibility Criteria
Inclusion Criteria
- Body mass index 27-40
- Waist > 96 cm
- Age 20-60 years
- Male
Exclusion Criteria
- Smoking
- Active health problems
- Contraindications to MRI scanning
- Bleeding tendency
- Abnormal liver or renal function tests
- Type 2 diabetes
- Evidence of metabolic or viral liver disease
- Alcohol intake > 21 units per week
- Chronic medication except ones needed for stable hypertension
Data sourced from ClinicalTrials.gov (NCT01445730). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.